MXPA03012021A - Metodo para mejorar la efectividad de las terapias contra el cancer. - Google Patents

Metodo para mejorar la efectividad de las terapias contra el cancer.

Info

Publication number
MXPA03012021A
MXPA03012021A MXPA03012021A MXPA03012021A MXPA03012021A MX PA03012021 A MXPA03012021 A MX PA03012021A MX PA03012021 A MXPA03012021 A MX PA03012021A MX PA03012021 A MXPA03012021 A MX PA03012021A MX PA03012021 A MXPA03012021 A MX PA03012021A
Authority
MX
Mexico
Prior art keywords
effectiveness
cancer therapies
enhancing
therapeutic material
galectins
Prior art date
Application number
MXPA03012021A
Other languages
English (en)
Spanish (es)
Inventor
Chang Yan
Original Assignee
Glycogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycogenesys Inc filed Critical Glycogenesys Inc
Publication of MXPA03012021A publication Critical patent/MXPA03012021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MXPA03012021A 2001-06-21 2002-06-21 Metodo para mejorar la efectividad de las terapias contra el cancer. MXPA03012021A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29999101P 2001-06-21 2001-06-21
US10/176,235 US6680306B2 (en) 2001-06-21 2002-06-20 Method for enhancing the effectiveness of cancer therapies
PCT/US2002/019885 WO2003000118A2 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies

Publications (1)

Publication Number Publication Date
MXPA03012021A true MXPA03012021A (es) 2004-06-03

Family

ID=26872020

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03012021A MXPA03012021A (es) 2001-06-21 2002-06-21 Metodo para mejorar la efectividad de las terapias contra el cancer.

Country Status (11)

Country Link
US (3) US6680306B2 (https=)
EP (1) EP1406639A4 (https=)
JP (1) JP2004535430A (https=)
CN (1) CN100558367C (https=)
AU (1) AU2002320140B2 (https=)
BR (1) BR0210550A (https=)
CA (1) CA2451841A1 (https=)
CZ (1) CZ200487A3 (https=)
IL (1) IL159461A0 (https=)
MX (1) MXPA03012021A (https=)
WO (1) WO2003000118A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) * 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
DE602004014485D1 (de) * 2003-04-07 2008-07-31 Prospect Therapeutics Inc Zusammensetzung und anwendungen von galectin-antagonisten
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
DE10335236B3 (de) * 2003-08-01 2005-02-24 Drägerwerk AG Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US20050282773A1 (en) * 2004-01-14 2005-12-22 Pro-Pharmaceuticals, Inc. Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
US20080286251A1 (en) * 2004-08-02 2008-11-20 Propharmaceuticals, Inc. Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
EP2184997A4 (en) * 2007-07-31 2010-11-03 Univ New York DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
ES2669068T3 (es) * 2011-12-08 2018-05-23 Eliaz Therapeutics, Inc Reducción de niveles de galectina-3 mediante plasmaféresis
MX363923B (es) * 2011-12-28 2019-04-08 Galectin Therapeutics Inc Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CA2875979C (en) 2012-06-06 2021-01-26 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
AU2013315019B2 (en) 2012-09-17 2017-06-01 Galectin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA2930817A1 (en) 2013-11-17 2015-05-21 Rdd Pharma Ltd. Methods for treating radiation induced gastrointestinal tract injury
CA3031691A1 (en) * 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
EP3621973A4 (en) 2017-05-12 2021-10-27 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF
WO2020136650A1 (en) 2018-12-25 2020-07-02 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an egfr inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107222A (en) * 1870-09-13 Improvement in machines for tenoning window-sash
US5490991A (en) 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5639737A (en) 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US20020107222A1 (en) 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5490911A (en) * 1993-11-26 1996-02-13 The United States Of America As Represented By The Department Of Energy Reactive multilayer synthesis of hard ceramic foils and films
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
WO1997033593A1 (en) * 1996-03-15 1997-09-18 Takara Shuzo Co., Ltd. A product of heat treatment of uronic acid, food, drink or drug including the product
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6274566B1 (en) * 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
EP1363673A2 (en) * 2000-09-25 2003-11-26 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
US20020104222A1 (en) * 2001-02-06 2002-08-08 Jay Larry Dean Knife for removing the hide of an animal and method therefor
US7012068B2 (en) * 2001-03-27 2006-03-14 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US6982255B2 (en) * 2001-03-27 2006-01-03 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6914055B2 (en) * 2001-03-27 2005-07-05 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases

Also Published As

Publication number Publication date
BR0210550A (pt) 2004-05-25
AU2002320140B2 (en) 2007-11-29
CA2451841A1 (en) 2003-01-03
US20040023925A1 (en) 2004-02-05
WO2003000118A2 (en) 2003-01-03
US20040043962A1 (en) 2004-03-04
CN100558367C (zh) 2009-11-11
US20030013681A1 (en) 2003-01-16
CN1543351A (zh) 2004-11-03
JP2004535430A (ja) 2004-11-25
IL159461A0 (en) 2004-06-01
US6680306B2 (en) 2004-01-20
WO2003000118A3 (en) 2003-04-10
EP1406639A2 (en) 2004-04-14
EP1406639A4 (en) 2004-07-28
CZ200487A3 (cs) 2004-10-13

Similar Documents

Publication Publication Date Title
MXPA03012021A (es) Metodo para mejorar la efectividad de las terapias contra el cancer.
IL188101A0 (en) Use of hif 1-alpha modulators for treatment of cancer
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
BRPI0513707A (pt) aplicador de braquiterapia intracavitária adaptativa
MXPA02011913A (es) Triazolopirimidinas sustituidas como agentes anticancer.
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
IL164599A0 (en) Combination therapy for the treatment of cancer
CA2361617A1 (en) Uses of thank, a tnf homologue that activates apoptosis
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
ATE408601T1 (de) Fredericamycin-derivate
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
GB0121490D0 (en) Ciompounds
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
WO2008076512A3 (en) Brachytherapy shielding system
MX2023011105A (es) Virus oncoliticos optimizados y usos de los mismos.
WO2004110245A3 (en) Combination therapy for cancer treatment
HUP0303649A2 (hu) Mátrix-metalloproteináz-inhibitorok liposzómás célzása
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
AU2002357644A8 (en) Therapeutic agents and corresponding treatments
DK1485345T3 (da) Urokinaseinhibitorer, deres fremstilling og anvendelse
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal